PLIVA, Inc. v. Mensing
The Supreme Court ruled that federal law blocks state lawsuits accusing generic drug makers of using inadequate warning labels, because federal rules require generic labels to always match the brand-name drug's label exactly.
The decision means that patients harmed by generic drugs generally cannot sue for failure-to-warn under state law, even though patients who took the brand-name version of the same drug can, creating a sharp legal divide based on which version a pharmacist happened to dispense.
How it got here: Federal trial courts allowed the failure-to-warn suits to proceed; the Fifth and Eighth Circuits both rejected the manufacturers' pre-emption defense, and the Supreme Court agreed to review both rulings together.
The Case in Depth
What happened
Gladys Mensing and Julie Demahy took generic metoclopramide, sold under the brand name Reglan, to treat digestive problems, and both developed a severe neurological movement disorder called tardive dyskinesia after years of use. They sued the generic manufacturers under Minnesota and Louisiana law, claiming the companies should have provided stronger warnings about the long-term risks of the drug.
The question before the Court
Could women harmed by long-term use of a generic anti-nausea drug sue the generic manufacturers for failing to warn about the drug's risks?
The Court's answer
No — the Court ruled that federal law pre-empts these state failure-to-warn claims against generic drug manufacturers. Because federal regulations require a generic drug's label to always match its brand-name counterpart's label, the manufacturers had no independent power to add a stronger warning on their own, even though state law required exactly that.
The Court rejected the argument that the manufacturers could have avoided the conflict by asking the FDA to help persuade the brand-name company to change the label first. Merely being able to request federal permission does not count as independently complying with a state-law duty, so the two duties directly conflicted and state law had to give way.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Because roughly three-quarters of prescriptions filled in the United States are generic, the ruling effectively cuts off a legal remedy for a large share of patients injured by inadequately labeled drugs. Whether an injured patient can sue now depends on the accident of whether her pharmacist filled her prescription with the brand-name or generic version.
What changes now
The Court reversed the Fifth and Eighth Circuits and sent the cases back for further proceedings consistent with the ruling, meaning Mensing's and Demahy's failure-to-warn claims are pre-empted and cannot proceed under state law. The decision is a final merits ruling that will govern future failure-to-warn suits against generic drug manufacturers nationwide, leaving Congress and the FDA as the only avenues for changing the underlying regulatory scheme.
What this does not decide
The Court did not decide whether generic manufacturers actually have a federal duty to ask the FDA for a label change; it assumed such a duty existed without resolving the dispute. It also left open whether conflict pre-emption can arise from grounds other than strict impossibility.
Concurrences and dissents
Dissent — Justice Sotomayor
“Until today, the mere possibility of impossibility had not been enough to establish pre-emption.”The dissent's central objection that the majority weakened the impossibility standard.
Justice Sotomayor argued the majority diluted the traditionally demanding impossibility standard, since the manufacturers never even tried asking the FDA to strengthen the label before claiming compliance was impossible. She would have required manufacturers to show, as in Wyeth, that the FDA would have rejected a proposed label change. She warned the ruling creates an arbitrary distinction between brand-name and generic drug consumers and undermines the presumption against pre-emption of state health and safety laws.
How the Court got there
The legal reasoning, step by step
- The Court compared the duty state tort law imposed on the manufacturers (to use a stronger, safer warning label) against what federal drug rules actually let generic manufacturers do to their labels on their own.
- Under the Hatch-Waxman Amendments, a 1984 law that created a fast-track approval process for generic drugs, a generic manufacturer's label must always match its brand-name counterpart's label rather than being independently written and defended like a brand-name label.
- Deferring to the FDA's own interpretation of its regulations, the Court found that generic manufacturers could not unilaterally strengthen their labels through the 'changes-being-effected' process or through letters to doctors; at most they could ask the FDA to work with the brand-name company to change the label for everyone.
- Applying the doctrine of impossibility pre-emption -- which asks whether a party can simultaneously obey conflicting state and federal duties -- the Court held that a manufacturer must be able to independently satisfy the state duty under federal law, and merely being able to ask a federal agency for permission does not count as independent compliance.
- Because asking the FDA for help would not by itself have satisfied the state-law duty to actually use a safer label, and using a safer label on their own would have violated the federal sameness requirement, the Court concluded the two duties directly conflicted.
- The Court distinguished this case from Wyeth v. Levine by noting that brand-name manufacturers, unlike generic ones, could change their own labels unilaterally under the CBE process, so federal law did not force the same conflict for brand-name drugmakers.
Doctrinal impact
Cases affected by this decision
Distinguishes Wyeth v. Levine (555 U. S. 555)
Brand-name manufacturers could unilaterally strengthen labels, so their claims were not pre-empted, unlike generic manufacturers here.